Table 1.
Clinicopathological characteristics of study patients (n = 88)
| Variables | N | % |
|---|---|---|
| Age at diagnosis (years) Median (range) | 51 | 26–74 |
| Age (years) | ||
| ≤ 50 | 41 | 46.6 |
| > 50 | 47 | 53.4 |
| Overall survival (months) | ||
| Median (range) | 74.77 | 1.60–103.13 |
| Number of deaths | 42 | 47.7 |
| Disease free survival (months) | ||
| Median (range) | 67.65 | 0.80–103.13 |
| Number of recurrences | 46 | 52.3 |
| Menopause | ||
| Yes | 45 | 51.1 |
| No | 43 | 48.9 |
| Laterality | ||
| Right side | 23 | 26.1 |
| Left side | 16 | 18.2 |
| Bilateral | 49 | 55.7 |
| Behavior | ||
| Borderline | 0 | 0 |
| Invasive | 88 | 100 |
| Histological subtype (%) | ||
| Serous | 59 | 67.0 |
| Non-serous | 29 | 33.0 |
| Histological grade (%) | ||
| G1 | 8 | 9.1 |
| G2 | 21 | 23.9 |
| G3 | 37 | 42.0 |
| Missing | 22 | 25.0 |
| FIGO (%) | ||
| I | 25 | 28.4 |
| II | 13 | 14.8 |
| III | 45 | 51.1 |
| IV | 5 | 5.7 |
| Intravascular tumor thrombus (%) | ||
| Yes | 16 | 18.2 |
| No | 69 | 78.4 |
| Missing | 3 | 3.4 |
| Serum CA 125 (U/mL) | ||
| < 35 | 11 | 12.5 |
| ≥ 35 | 63 | 71.6 |
| Missing | 14 | 15.9 |
| Serum CA 19-9 (U/mL) | ||
| < 37 | 38 | 43.2 |
| ≥ 37 | 18 | 20.5 |
| Missing | 32 | 36.4 |
| Serum CEA (ng/mL) | ||
| < 5 | 58 | 65.9 |
| ≥ 5 | 2 | 2.3 |
| Missing | 28 | 31.8 |
| Chemotherapy | ||
| Yes | 83 | 94.3 |
| Missing | 5 | 5.7 |
| Traditional Chinese medicine treatment | ||
| Yes | 18 | 20.5 |
| No | 70 | 79.5 |
| APOBEC3B | ||
| − | 8 | 9.1 |
| + | 32 | 36.4 |
| ++ | 32 | 36.4 |
| +++ | 16 | 18.2 |
APOBEC3B apolipoprotein B mRNA editing enzyme catalytic subunit 3B, CA 125 cancer antigen 125, CA 19-9 cancer antigen 19-9, CEA carcinoembryonic antigen, FIGO Federation of Gynecologists and Obstetricians